ANIP (ANI Pharmaceuticals Inc) Net Profit

Corporate emblem and logo of anipharmaceuticals.com (ANIP)

Commoditization of core assets is constraining growth, but the success of new gels is creating momentum for ANI Pharmaceuticals (ANIP). The company's financial success metric reflects this volatility, with the current level standing at 0.10. A focus on complex generics and R&D provides stability. Confidence is further bolstered by the full automation of production lines, which eliminates manual labor and guarantees the sterility of the output.

ANIP (ANI Pharmaceuticals, Inc.) Company Net Income history from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for ANI Pharmaceuticals, Inc. (ANIP)

- price and consensus price forecast:
Stock Quotes ANI Pharmaceuticals Corp|ANIP - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization ANI Pharmaceuticals Corp|ANIP - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share ANI Pharmaceuticals|ANIP - Company Book Value|Market-to-Book Ratio anipharmaceuticals.com|ANIP - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital ANI Pharmaceuticals|ANIP - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital ANI Pharmaceuticals Inc|ANIP - Company Aggregate Debts|Debts to Book Value ANI Pharmaceuticals Corp|ANIP - Company Long-Term Debt|Company Short-Term Loans and Borrowings ANI Pharmaceuticals|Quick Ratio anipharmaceuticals.com
- net income and valuation multiples indicators:
ANIP - Company Net Income
Fundamental valuation:ANIP ANI Pharmaceuticals Corp
Flagship merchandise of ANI Pharmaceuticals Inc

Net income reflects the final financial result after deducting all operating and tax expenses, serving as a measure of business capitalization efficiency. By analyzing the profit of ANI Pharmaceuticals (ANIP), an investor can assess the extent to which the company's M&A strategy of acquiring generic portfolios translates into actual cash flow, identifying hidden integration costs of new assets or synergies from expanded distribution.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|MannKind Corp - Final Profit|AMPH (Amphastar) - Net Profit|Company Net Income Pacira Corp PCRX|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Net Profit AQST (Aquestive Therapeutics, Inc.)|Net Profit scPharmaceuticals, Inc. SCPH|TECX - Company Net Income|TNXP (Tonix Pharmaceuticals Holding) - Company Profit|SXTC: Net Profit|EPRX - Net Financial Result|Net Income BHST|EXOZ: Final Profit|Company Net Income Oramed Pharmaceuticals (ORMP)|ENTX: Profit After Tax|Net Profit HYFT (MindWalk Holdings)|Final Profit ABVC|Cumberland Pharmaceuticals Inc. - Net Profit|QNTM - Net Profit|FibroGen Corp (FGEN) - Company Net Income|Telomir Pharmaceuticals Corp - Final Profit|Company Net Income Rani Therapeutics Holdings|Net Income Synergy CHC Corporation (SNYR)|Net Profit RLYB|Net Profit lexariabioscience.com (LEXX)|Net Profit PULM (Pulmatrix Corp)|PTHL - Net Income|Aptorum - Net Profit|Company Net Income lyratherapeutics.com|IBO (Impact BioMedical Inc) - Net Income|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|Net Income YCBD|PRFX (PainReform Corp) - Profit After Payment of Taxes|Net Profit CYTO|Net Financial Result lipella.com|Net Profit OPTN (OptiNose)|PIRS - Net Income|Procaps Group SA - Net Profit|PTPI - Net Profit|Qilian International (QLI) - Company Net Income|SLRN (acelyrin.com) - Company Net Income|Company Net Income TFF Pharmaceuticals, Inc.